1. Introduction
Malaria is still regarded as a major global infectious disease
in the 21st century, with a high pediatric mortality toll in the
developing world [1]. In Africa, malaria is one of the diseases
causing the most morbidity and mortality. The number of
Africans who die as a result of malaria each year is estimated
at 800 000 people of which a greater proportion is children
aged below 5 years [2]. This is coupled with the emergence
and spread of parasite resistance to well-established antimalarial
drugs and mosquito vectors resistant to insecticides. It is
therefore evident that newer agents with improved efficacy and